48,830
edits
Difference between revisions of "Eosinophilic, solid and cystic renal cell carcinoma"
Jump to navigation
Jump to search
Eosinophilic, solid and cystic renal cell carcinoma (view source)
Revision as of 03:16, 25 April 2024
, 25 Aprilno edit summary
| Line 11: | Line 11: | ||
| IHC = [[PAX8]] +ve, [[CK20]] +ve, [[CK7]] -ve, CA9 -ve, CD117 -ve, HMB-45 -ve | | IHC = [[PAX8]] +ve, [[CK20]] +ve, [[CK7]] -ve, CA9 -ve, CD117 -ve, HMB-45 -ve | ||
| EM = | | EM = | ||
| Molecular = | | Molecular = [[Renal neoplasms with TSC/mTOR pathway mutations|TSC/mTOR pathway mutations]] | ||
| IF = | | IF = | ||
| Gross = solid and cystic | | Gross = solid and cystic | ||
| Line 109: | Line 109: | ||
*CA9 -ve. | *CA9 -ve. | ||
*HMB-45 -ve. | *HMB-45 -ve. | ||
==Molecular== | |||
*[[Renal neoplasms with TSC/mTOR pathway mutations|TSC/mTOR pathway mutations]].<ref name=pmid35203531>{{cite journal |authors=Pivovarcikova K, Alaghehbandan R, Vanecek T, Ohashi R, Pitra T, Hes O |title=TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background |journal=Biomedicines |volume=10 |issue=2 |pages= |date=January 2022 |pmid=35203531 |pmc=8869370 |doi=10.3390/biomedicines10020322 |url=}}</ref> | |||
==See also== | ==See also== | ||